Cardiac Power Output (CPO)
Measures cardiac mechanical power — strongest haemodynamic predictor of mortality in cardiogenic shock. CPO = (MAP × CO) / 451.
Score interpretation
At or above the 0.6 W target used in cardiogenic shock protocols; normal resting CPO is about 1 W.
→ Continue current haemodynamic management; reassess with any clinical change.
Below the 0.6 W target used in cardiogenic shock protocols.
→ Close haemodynamic monitoring. Optimise volume status, afterload and contractility; senior / cardiology review.
CPO ≤ 0.53 W was the strongest haemodynamic correlate of in-hospital death in cardiogenic shock (SHOCK registry, Fincke 2004).
→ Initiate cardiogenic shock protocol. Consider MCS (IABP/Impella/ECMO). Urgent cardiology/CCU review.
Interpretation bands for the CPO. Apply clinical judgement and local guidance.
References
- Fincke R et al. Cardiac power is the strongest hemodynamic correlate of mortality in cardiogenic shock. J Am Coll Cardiol. 2004;44(2):340-348.
Related
Curated clinical cross-links plus same-class fallbacks.
- Noradrenaline (Cardiogenic Shock / Vasopressor) · Vasopressor / Cardiogenic Shock
- Hydrocortisone (ICU — Stress Dosing) · Corticosteroid (ICU/Septic Shock)
- Lidocaine IV (Cardiac Arrhythmia) · Antiarrhythmic
- Protamine Sulphate (Heparin Reversal) · Heparin Reversal / Cardiac Surgery
- Mavacamten · Cardiac myosin inhibitor
- Vasopressin / Terlipressin · Vasopressin Analogue — Vasodilatory Shock / Variceal Bleeding
- Acute Heart Failure · ESC 2021 Heart Failure Guidelines; NICE NG106
- NSTEMI / Unstable Angina · ESC 2020 NSTEMI Guidelines; NICE NG185
- New-Onset Atrial Fibrillation · ESC 2020 AF Guidelines; NICE NG196
- Hypertensive Emergency · ESC/ESH 2018 Hypertension Guidelines; NICE NG136
- Bradycardia Management · Resuscitation Council UK ABCDE; ESC 2021 Pacing Guidelines
- Ventricular Tachycardia / Fibrillation · Resuscitation Council UK ACLS; ESC 2022 Ventricular Arrhythmia Guidelines
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.